<DOC>
	<DOCNO>NCT01051102</DOCNO>
	<brief_summary>This trial conduct Japan . The aim clinical trial investigate blood sugar lower effect NN5401 ( insulin degludec/insulin aspart ( IDegAsp ) ) Japanese subject type 1 diabetes . Each subject randomise one two possible treatment sequence ( NN5401 follow biphasic insulin aspart ( BIAsp ) 30 biphasic insulin aspart 30 follow NN5401 ) .</brief_summary>
	<brief_title>Effect NN5401 Japanese Subjects With Type 1 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec , insulin aspart drug combination</mesh_term>
	<mesh_term>Insulin aspart , insulin aspart protamine drug combination 30:70</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Biphasic Insulins</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<mesh_term>Insulin , Isophane</mesh_term>
	<criteria>Japanese subject Type 1 diabetes mellitus ( diagnose clinically ) least 12 month Body mass index ( BMI ) : 18.028.0 kg/m^2 ( inclusive ) Loss 400 mL blood ( inclusive ) total last 12 week 200 mL blood ( inclusive ) total within last 4 week prior screen Smoker ( define subject smoke 5 cigarette ( inclusive 5 ) equivalent per day ) Not able willing refrain smoking use nicotine gum transdermal nicotine patch inpatient period</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>